TY  - GEN
AU  - Rogers,G
AU  - Hoyle,M
AU  - Thompson Coon,J
AU  - Moxham,T
AU  - Liu,Z
AU  - Pitt,M
AU  - Stein,K
TI  - Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
SN  - 2046-4924
PY  - 2012///0905
KW  - Benzamides
KW  - Blast Crisis
KW  - drug therapy
KW  - Clinical Trials as Topic
KW  - Cost-Benefit Analysis
KW  - Dasatinib
KW  - Decision Support Techniques
KW  - Disease Progression
KW  - Drug Resistance, Neoplasm
KW  - Health Care Costs
KW  - statistics & numerical data
KW  - Humans
KW  - Imatinib Mesylate
KW  - Incidence
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Leukemia, Myeloid, Accelerated Phase
KW  - Leukemia, Myeloid, Chronic-Phase
KW  - Models, Economic
KW  - Piperazines
KW  - pharmacology
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - economics
KW  - Pyrimidines
KW  - Quality of Life
KW  - Thiazoles
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
UR  - https://doi.org/10.3310/hta16220
ER  -